Impel NeuroPharma Appoints Jennifer L. Berman As Vice President Of Marketing

SEATTLE, Feb. 19, 2019 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that Jennifer L. Berman has joined the Company as the Vice President of Marketing. 

"We are delighted to welcome Jennifer to the Impel team as we continue to advance our mid-to-late stage CNS assets focused on migraine, Parkinson's disease and agitation," said Jon Congleton, President and Chief Executive Officer of Impel NeuroPharma. "Jennifer's expertise in U.S. and global marketing, including launching major CNS brands, makes her an outstanding addition to our growing team."

Jennifer brings to Impel more than 15 years of marketing leadership experience in the pharmaceutical and medical device industry. Most recently she served as the Worldwide Brand Director at Novartis Pharmaceuticals Corporation, where she was the global launch lead for Aimovig®, the first monoclonal antibody approved by the U.S. Food and Drug Administration for migraine prevention. She previously served as Senior Director of Global Marketing at electroCore, LLC, Senior Product Manager at BIOMET and Vice President of Marketing at Sepal Reproductive Devices.

"I believe Impel's exciting new approach to treating serious CNS diseases with significant unmet needs via the POD® technology platform represents an opportunity to bring desired clinical outcomes to patients," said Jennifer. "I am thrilled to be joining the team at such a critical point in the Company's journey to becoming a commercial-stage organization and I look forward to working closely with the migraine, Parkinson's and mental health communities."

Jennifer received her Bachelor of Science in business administration from Babson College.

About Impel NeuroPharma 
Impel NeuroPharma, Inc., is a privately-held, Seattle-based biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Impel NeuroPharma is currently investigating INP104 (POD-DHE) for acute migraine headache, INP103 (POD-levodopa) for reversal of OFF episodes in Parkinson's disease and INP105 (POD-olanzapine) for acute agitation in schizophrenia and bipolar disorders.

Impel's products utilize its novel, nasal drug-delivery Precision Olfactory Delivery, or POD, device technology to deliver liquid or dry powder forms of drug to the upper nasal cavity in a consistent and predictable manner.

IMPEL, POD and the IMPEL Logo are trademarks of Impel NeuroPharma, Inc. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com.

Contact: 
Melyssa Weible 
Elixir Health Public Relations 
Ph: (1) 201-723-5805 
E: [email protected]

SOURCE Impel NeuroPharma

Related Links

http://impelnp.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED